StockNews.AI

Serina Therapeutics Receives NYSE Deficiency Notification Regarding Shareholders' Equity

StockNews.AI • 7 hours

PFE
High Materiality8/10

Information

HUNTSVILLE, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") ...

Original source

AI Summary

Serina is below NYSE listing criteria due to low stockholders' equity. Serina must submit a compliance plan by February 2026. If unaccepted, delisting proceedings will Commence. Serina's SER-252 aims to treat advanced Parkinson's disease. POZ technology enhances drug delivery for various indications.

Sentiment Rationale

Non-compliance with NYSE listing standards raises serious doubts about Serina's future viability. Historical examples show that firms losing compliance face substantial investor concerns, often leading to sharp declines in stock prices.

Trading Thesis

Immediate concerns will manifest in the stock price as investors react to the compliance deadline and potential delisting. Previous incidents with biotech stocks displaying similar issues often resulted in market volatility within weeks to months.

Market-Moving

  • Serina is below NYSE listing criteria due to low stockholders' equity.
  • Serina must submit a compliance plan by February 2026.
  • If unaccepted, delisting proceedings will Commence.

Key Facts

  • Serina is below NYSE listing criteria due to low stockholders' equity.
  • Serina must submit a compliance plan by February 2026.
  • If unaccepted, delisting proceedings will Commence.
  • Serina's SER-252 aims to treat advanced Parkinson's disease.
  • POZ technology enhances drug delivery for various indications.

Companies Mentioned

  • PFE (PFE)

Corporate Developments

The notice from the NYSE signifies a critical juncture for Serina, impacting investor confidence. Negative sentiment around compliance and potential delisting significantly affects market perception and trading behavior.

Serina Therapeutics Receives NYSE Deficiency Notification Regarding Shareholders' Equity

HUNTSVILLE, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER) has announced that it received a deficiency notice from the New York Stock Exchange (NYSE). The notification indicates that Serina is below the continued listing criteria under Sections 1003(a)(i) and (ii) of the NYSE's listing standards. This development comes after the Company reported stockholders' equity of $1.6 million as of September 30, 2025, alongside operating losses in three of its last four fiscal years ending December 31, 2024.

Details of the NYSE Notification

According to the NYSE letter, Serina is not currently eligible for any exemption outlined in Section 1003(a) regarding stockholders' equity requirements. In response to this non-compliance, the Company must submit a plan by February 8, 2026, outlining the actions it will take to meet the continued listing standards by July 9, 2027, marking an eighteen-month "Cure Period."

If the NYSE American accepts Serina's compliance plan, the Company can maintain its listing during the Cure Period, subject to periodic reviews and quarterly monitoring. However, failure to gain acceptance for the plan will result in the commencement of delisting proceedings.

About Serina Therapeutics and SER-252

Serina Therapeutics is a clinical-stage biotechnology company based in Huntsville, Alabama, focused on developing drug candidates for neurological diseases and other medical indications. The Company’s lead Investigational New Drug (IND) candidate, SER-252, utilizes the proprietary POZ PlatformTM for enhanced drug optimization.

SER-252 is an investigational apomorphine therapy aimed at providing continuous dopaminergic stimulation (CDS), thereby reducing severe motor complications associated with Parkinson's disease. Preclinical studies indicate that SER-252 may offer CDS without the adverse skin reactions often linked to similar therapies.

Understanding the POZ PlatformTM

The POZ PlatformTM is based on a synthetic, water-soluble polymer known as poly(2-oxazoline). This innovative technology is designed to improve the efficacy and safety profiles of various drug modalities, including small molecules and RNA-based therapeutics. Through enhanced drug loading control and precise release rates, Serina aims to deliver therapeutic agents that are effective yet limited by traditional pharmacokinetic profiles.

The adaptability of the POZ platform also positions it for potential applications across a range of medical indications, including a non-exclusive license agreement with Pfizer, Inc. for lipid nanoparticle drug delivery formulations.

Forward-Looking Statements and Risks

This announcement contains forward-looking statements as defined by federal securities laws. These statements include expectations regarding the Company's future performance, response to the FDA's clinical hold letter, and anticipated timelines for clinical programs. However, actual results may vary significantly due to various uncertainties and risks, including research and development challenges, regulatory approval timelines, and potential market competition.

Stakeholders are encouraged to review the risks and uncertainties detailed in Serina’s Annual Report on Form 10-K for the year ended December 31, 2024, as well as other periodic reports filed with the SEC.

Contact Information

For further inquiries regarding this announcement, please contact:

Related News